Intranasal vaccination with a Newcastle disease virus-vectored vaccine protects hamsters from SARS-CoV-2 infection and disease
| Autor: | Jonathan Audet, Sarah K. Wootton, Byram W. Bridle, Lily Chan, Lisa A. Santry, Logan Banadyga, Emelissa J. Valcourt, Darwyn Kobasa, Leonardo Susta, Kathy L. Frost, Marnie Willman, Anders Leung, Jessica A. Minott, Robert C. Mould, Nikesh Tailor, Alixandra Albietz, Bryce M. Warner, Jason P. Knapp, Pierre Major, Yanlong Pei, Yeganeh Mehrani, Robert Vendramelli, Phuc H. Pham, Kevin Tierney, Alexander Leacy, Heidi Wood, Jacob G. E. Yates, Mable Chan, David Safronetz, Stephanie A. Booth, Shihua He, Bryan D. Griffin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Science viruses Newcastle disease virus lyophilization Inflammation spike protein Newcastle disease Virus Article Disease Outbreaks Immune respons avian orthoavulavirus-1 Virology Pandemic Medicine Humans viral vectored vaccine skin and connective tissue diseases Multidisciplinary Lung lung pathology biology business.industry mucosal immunization SARS-CoV-2 Vaccination COVID-19 respiratory system biochemical phenomena metabolism and nutrition biology.organism_classification intranasal vaccination respiratory tract diseases Titer medicine.anatomical_structure Nasal administration medicine.symptom business |
| Zdroj: | iScience iScience, Vol 24, Iss 11, Pp 103219-(2021) |
| ISSN: | 2589-0042 |
| Popis: | The pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease 2019 (COVID-19). Worldwide efforts are being made to develop vaccines to mitigate this pandemic. We engineered two recombinant Newcastle disease virus (NDV) vectors expressing either the full-length SARS-CoV-2 spike protein (NDV-FLS) or a version with a 19 amino acid deletion at the carboxy terminus (NDV-Δ19S). Hamsters receiving two doses (prime-boost) of NDV-FLS developed a robust SARS-CoV-2-neutralizing antibody response, with elimination of infectious virus in the lungs and minimal lung pathology at five days post-challenge. Single-dose vaccination with NDV-FLS significantly reduced SARS-CoV-2 replication in the lungs, but only mildly decreased lung inflammation. NDV-Δ19S-treated hamsters had a moderate decrease in SARS-CoV-2 titers in lungs and presented with severe microscopic lesions, suggesting that truncation of the spike protein was a less effective strategy. In summary, NDV-vectored vaccines represent a viable option for protection against COVID-19. Graphical Abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|